<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1159">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02833792</url>
  </required_header>
  <id_info>
    <org_study_id>STEM105-M-AD</org_study_id>
    <nct_id>NCT02833792</nct_id>
  </id_info>
  <brief_title>Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease</brief_title>
  <official_title>A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stemedica Cell Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stemedica International SA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stemedica Cell Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      STUDY OBJECTIVES&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      To assess the safety and tolerability of ischemia-tolerant allogeneic human mesenchymal stem&#xD;
      cells (hMSCs) manufactured by Stemedica versus placebo administered intravenously to subjects&#xD;
      with mild to moderate dementia due to Alzheimer's disease.&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
      To assess the preliminary efficacy of hMSCs versus placebo in subjects with&#xD;
      Alzheimer's-related dementia, as evidenced by neurologic, functional, and psychiatric&#xD;
      endpoints.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase IIa multi-center, randomized, single-blind, placebo-controlled, crossover&#xD;
      study in subjects with mild to moderate dementia due to Alzheimer's disease. Only the subject&#xD;
      and their caregiver will be blinded to the study treatment. The study will consist of two&#xD;
      cohorts of subjects (20 subjects per cohort), randomized in a 1:1 allocation to receive&#xD;
      active study drug or placebo. Cohort 1 will receive a single intravenous dose of hMSCs of 1.5&#xD;
      million cells per kilogram body weight on their Study Day 1, and Cohort 2 will receive equal&#xD;
      volume of Lactated Ringer's Solution on their Study Day 1. At the six-month time point for&#xD;
      each subject after their first infusion, Cohort 1 will receive a single intravenous dose of&#xD;
      Lactated Ringer's Solution and Cohort 2 will receive a single intravenous dose of hMSCs at&#xD;
      1.5 million cells per kilogram of the subject's body weight. Approximately 40 subjects will&#xD;
      be enrolled in this study. An independent Data and Safety Monitoring Board will conduct&#xD;
      periodic safety reviews.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of aMBMC administration</measure>
    <time_frame>18 months</time_frame>
    <description>Number of patients with adverse events will be reported</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of aMBMC administration</measure>
    <time_frame>18 months</time_frame>
    <description>Changes is scores relatively to baseline using NIHSS system will be reported for each patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Alzheimer Dementia</condition>
  <arm_group>
    <arm_group_label>Stem Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lactated Ringer's Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Mesenchymal Stem Cells and Lactated Riunger's Solution</intervention_name>
    <description>Intravenous administration</description>
    <arm_group_label>Stem Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females between 55-80 years of age.&#xD;
&#xD;
          2. Diagnosed with mild to moderate dementia for at least 3 months prior to enrollment,&#xD;
             based on the National Institute of Neurological and Communicative&#xD;
&#xD;
          3. Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association&#xD;
             (NINDS-ADRDA) Alzheimer's criteria.&#xD;
&#xD;
          4. MMSE between 12-24 (inclusive) at time of enrollment.&#xD;
&#xD;
          5. Amyloid-positive florbetapir PET scan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with stem cells.&#xD;
&#xD;
          2. History of intracranial, subdural, or subarachnoid hemorrhage.&#xD;
&#xD;
          3. Subjects with baseline brain MRI showing more than four (4) cerebral microhemorrhages&#xD;
             (regardless of their anatomical location or diagnostic characterization as &quot;possible&quot;&#xD;
             or &quot;definite&quot;), and/or one (1) or more areas of superficial siderosis, and/or evidence&#xD;
             of a prior macrohemorrhage. MRI must include fluid-attenuation inversion recovery&#xD;
             (FLAIR) and T2*-weighted gradient-recalled-echo (GRE) sequences.&#xD;
&#xD;
          4. History of cancer within the past 5 years, with the exception of localized basal or&#xD;
             squamous cell carcinoma.&#xD;
&#xD;
          5. History of seizure disorder.&#xD;
&#xD;
          6. Diagnosis of cerebral autosomal dominant arteriopathy with subcortical infarcts and&#xD;
             leukoencephalopathy (CADASIL).&#xD;
&#xD;
          7. History of cerebral neoplasm.&#xD;
&#xD;
          8. Myocardial infarction within six months of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lev Verkh, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Stemedica Cell Technologies</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lev Verkh, PhD</last_name>
    <phone>858-658-0910</phone>
    <email>lverkh@stemedica.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcie Frank, RN BSN</last_name>
    <phone>858-658-0910</phone>
    <email>mfrank@stemedica.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>John Wayne Cancer Institute @ Providence St. John's Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mini Gill, RN BSN</last_name>
      <phone>310-582-7437</phone>
      <email>Jaya.Gill@providence.org</email>
    </contact>
    <investigator>
      <last_name>Santosh Kesari, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://stemedica.com</url>
    <description>Sponsor information</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>October 27, 2022</last_update_submitted>
  <last_update_submitted_qc>October 27, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

